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ABSTRACT 
Purpose. The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial 
designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women 
with stage II/III breast cancer. Here we report the safety and tolerability profile of ZOL in this 
setting. 
Patients and methods. Eligible patients received (neo)adjuvant chemotherapy and/or 
endocrine therapy and were randomised to receive either no additional treatment or 
intravenous ZOL 4mg. ZOL was administered after each chemotherapy cycle to exploit 
potential sequence dependent synergy. ZOL was continued for 60 months post-
randomisation (6 doses in the first 6 months, 8 doses in the following 24 months and 5 
doses in the final 30 months). Serious (SAE) and non-serious adverse event (AE) data 
generated during the first 36 months on study were analysed for the safety population. 
Results. 3360 patients were recruited to the AZURE trial. The safety population comprised 
3340 patients (ZOL 1665; control 1675). The addition of ZOL to standard treatment did not 
significantly impact on chemotherapy delivery. SAE were similar in both treatment arms. No 
significant safety differences were seen apart from the occurrence of osteonecrosis of the 
jaw (ONJ) in the ZOL group (11 confirmed cases; 0.7%; 95% confidence interval 0.3% to 
1.1%).  
Conclusions. ZOL in the adjuvant setting is well tolerated, and can be safely administered in 
addition to adjuvant therapy including chemotherapy. The adverse events were consistent 
with the known safety profile of ZOL, with a low incidence of ONJ.  
 
Key words: Breast cancer; zoledronic acid; adjuvant therapy; safety; osteonecrosis of the 
jaw. 
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BACKGROUND 
Despite significant advances in the adjuvant treatment of early breast cancer, the disease 
still results in approximately 410,000 global deaths each year [1,2]. dŚĞ  “hZ ?ƉŚĂƐĞ ///
trial is investigating whether addition of the bisphosphonate zoledronic acid (ZOL) to 
standard adjuvant treatments further improves the disease-free survival (DFS) of stage II/III 
breast cancer patients. 
 
Widely used in benign and malignant bone diseases, the bisphosphonates have become 
familiar agents in routine clinical practice. ZOL is a bisphosphonate that efficiently inhibits 
osteoclast function, resulting in profound inhibition of bone resorption. Additionally a body 
of evidence is emerging that describes anti-tumour activity of bisphosphonates, including 
evidence of synergy with cytotoxic agents[3,4]. In the clinical setting, a phase III study in 
1,800 pre-menopausal women with oestrogen receptor positive disease, demonstrated a 
36% reduction in the risk of developing recurrent disease from the addition of ZOL to 
endocrine therapy [5]. 
 
Bisphosphonates are generally well tolerated, with renal dysfunction [6] and osteonecrosis 
of the jaw (ONJ) the only clinically important toxicities associated with their use [7,8]. 
However, combining ZOL with chemotherapy has the potential for enhanced toxicity, 
especially if there is a synergistic interaction with chemotherapy on normal tissues. Safety 
evaluation within the AZURE trial is the ideal opportunity to assess this. Here we report the 
largest dataset evaluating safety of ZOL outside the metastatic setting and the first analysis 
at this intensive dosing schedule addressing specific adverse events of note including renal 
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and cardiovascular effects, outcomes of pregnancies and ONJ as well as potential effects on 
chemotherapy related side-effects such as neutropaenic fever and mucositis. 
  
PATIENTS AND METHODS 
AZURE is a multi-centre, international, open label, randomised parallel group trial 
(ISRCTN79831382). Figure 1 shows the trial schema. Eligible patients were women with 
stage II/III breast cancer scheduled to receive (neo)adjuvant chemotherapy and/or 
endocrine therapy, of ECOG performance status 0- ? ĂŶĚ ĂŐĞĚ A? ? ? ǇĞĂƌƐ ? WĂƚŝĞŶƚƐ ǁith 
abnormalities of bone metabolism, prior treatment with bisphosphonates within 1 year, or 
evidence of renal impairment (serum creatinine >1.5 times upper limit of normal) were 
excluded. All patients gave written informed consent before study entry. 
 
ZOL was administered at a dose of 4mg intravenous (i.v.) over 15 minutes. Dose reductions 
and interuptions for renal impairment (calculated creatinine clearance <60ml/minute) were 
as specified by the current prescribing information. Chemotherapy- or endocrine-related 
toxicities were handled according to local protocols. 
 
Baseline and safety assessments 
Safety assessments consisted of recording and immediate reporting of all serious adverse 
events (SAEs), recording of adverse events (AEs) potentially related to either treatment or 
the disease process using Common Toxicity Criteria (CTC) [9], regular monitoring of blood 
chemistry and physical examinations. AEs considered unrelated to the study drug, cancer 
treatment(s) or the disease process were not routinely collected. SAEs were described 
according to duration, seriousness, relationship to study drug or underlying cancer and any 
 5 
action taken. Serum creatinine was measured at baseline and every treatment visit for 
patients receiving ZOL. In the control arm, renal monitoring was required at baseline, three 
and six months and then at the same frequency as the ZOL arm. 
 
SAEs were sent to the Clinical Trials Research Unit (CTRU), Leeds, whilst non-serious AE data 
were sent to the local participating  clinical trials units. All safety data were overseen by an 
independent Data Monitoring and Ethics Committee. Additionally, a Trial Steering 
Committee (TSC) was established to provide overall supervision of the trial including patient 
safety.  
 
In February 2004, following the emergence of a potential link between ONJ and 
bisphosphonates [10], the patient information sheet was revised to address this possible 
risk and consent was re-obtained for those patients already enrolled. The protocol was 
amended in July 2005 to exclude patients with significant active dental problems or recent 
jaw surgery. In May 2006, dental hygiene advice was distributed to all patients, and 
guidance on the diagnosis, prevention and treatment of ONJ based on emerging clinical 
guidelines provided to all investigators. Investigators were requested to report all possible 
cases of ONJ as serious adverse events for central review. This triggered a request for 
additional detailed information on clinical features, prior dental interventions, imaging and 
ďŝŽƉƐǇ ƌĞƐƵůƚƐ ĨŽƌ ĐĞŶƚƌĂů ƌĞǀŝĞǁ ?  ĚŝĂŐŶŽƐŝƐ ŽĨ KE: ǁĂƐ  “ĐŽŶĨŝƌŵĞĚ ? ŝĨ ƚŚĞ ĚĞƐĐƌŝƉƚŝŽŶ
conformed to the definition stipulated in the guidance documents from the American 
Association of Oro-Maxillary Surgeons (AAOMS)[11] and the American Association for Bone 
and Mineral Research (ASBMR) [8]. All other cases reported by investigators were classified 
ĂƐ “ƉŽƐƐŝďůĞKE: ? ? 
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Statistical methods 
Patients were stratified by participating centre and randomised using minimisation to 
ensure lymph node involvement, tumour stage, ER status, type of adjuvant systemic 
therapy, use of statins and menopausal status were similar in both arms.  
 
Two time periods have been evaluated: i) randomisation to 6 months to capture safety 
information during (neo)adjuvant chemotherapy and ii) 6 months to 3 years to represent 
the follow-up period when ZOL was given alone in the treatment arm (+/- endocrine 
treatments according to ER status or trastuzumab for HER2 positive patients recruited 
during 2005/6). 
 
ONJ rates were calculated using cumulative incidence functions, where deaths without 
diagnosis of ONJ were considered competing-risk events, and compared using the log-rank 
test. Patients without evidence of ONJ were censored at date of death or the last date they 
were known to be alive.  Hypothesis testing was at the 5% significance level (2-sided) and 
performed using SAS version 9.2 (SAS Institute Inc., Cary, NC). 
 
Safety population 
This safety analysis includes data from the first 3 years of follow up from randomisation for 
which we have complete data in approximately 95% of patients. Patients are included in the 
treatment group to which they were randomised.  In the treatment arm, patients who did 
not receive any ZOL have been excluded from the safety population. Control patients who 
received ZOL at a later visit (regardless of the reason) have been censored at the time of 
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first administration.  Patients who developed distant metastasis have been censored at the 
time this was confirmed. 
 
RESULTS 
Patient population 
The AZURE trial recruited 3360 patients between September 2003 and February 2006 from 
174 centres. The safety population comprises 3340 patients, 1675 patients in the control 
arm (CONTROL) and 1665 patients in the zoledronic acid arm (ZOL). 1600 CONTROL and 
1590 ZOL patients received chemotherapy. The treatment groups were well balanced in 
terms of baseline characteristics (table 1).  
 
Chemotherapy phase (randomisation  ? 6 months) 
Overall safety profile 
The addition of 3-4 weekly ZOL to standard treatment did not affect tolerability or safety of 
systemic treatment. The most frequent AEs occurring in >10% of patients are listed in table 
2. The proportions of patients reporting one or more AEs were similar (CONTROL 91.4% 
versus (vs) ZOL 93.1%). The median number of AEs per patient was equal in both groups 
(n=14, range 1-75).  45031 AEs were reported in total (CONTROL 22255 vs ZOL 22776); 
grade 3 or 4 AEs reported were of similar frequency (CONTROL 1035 [4.7%] vs. ZOL 1116 
[4.9%]).  Myalgia/arthralgia was the only AE to show a significant difference in frequency 
(CONTROL  374 [23.4%] vs ZOL  456 [28.7%]; p=<.05), probably reflecting the well 
characterised acute phase response to zoledronic acid. 
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SAEs were reported among 22.0% (352/1600) and 24.5% (389/1590) of patients in the 
CONTROL and ZOL groups respectively (Table 3). 1007 SAEs were reported in total 
(CONTROL 480 vs. ZOL 527). Amongst patients receiving ZOL, the SAE was suspected to be 
related to ZOL in 14 (2.7%): pyrexia (n=7), anaphylactic reaction (n=2), ONJ (n=1), pain (n=1), 
vomiting (n=1), iritis (n=1) and elevated creatinine (n=1). The most common SAE was 
neutropenic sepsis (CONTROL 9.3% vs. ZOL 9.4%). All other SAEs occurred in less than 3% of 
patients.  
 
Chemotherapy duration and dose reductions 
The median duration of chemotherapy delivery was similar in both groups (CONTROL 4.0 
months vs. ZOL 3.9 months). Chemotherapy dose reductions were required in 230/1600 
[14.4%] CONTROL and 209/1590 (13.1%) ZOL patients. The duration of chemotherapy and 
number of dose reductions were similar in both the neoadjuvant and post-operative 
settings (data not shown).  
 
Renal toxicity 
Serum creatinine data were available for 3278 (98%) patients (CONTROL 1648 vs. ZOL 1630). 
Mean baseline serum creatinine levels were similar (CONTROL 73.6mmol/l [S.D. 13.87] vs. 
ZOL 73.7mmol/l [S.D. 13.64]), and remained similar to baseline levels in both groups.  During 
the adjuvant chemotherapy phase, renal failure was reported as an SAE in 3 cases 
(CONTROL 1 vs. ZOL 2). The 2 cases in the ZOL group were reported as not suspected to be 
related to the bisphosphonate. Additionally, increases in serum creatinine of any CTC grade 
were uncommon (CONTROL 0.5% vs. ZOL 0.4%). ZOL was delayed in accordance with the 
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ƉƌŽĚƵĐƚĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐŝŶ ?ƉĂƚŝĞŶƚƐĂŶĚ ?ŽƌƚŚĞĚŽƐĞƌĞĚƵĐĞĚĂƚƚŚĞĐůŝŶŝĐŝĂŶ ?ƐĚŝƐĐƌĞƚŝŽŶŝŶ
6 patients due to a decline in calculated creatinine clearance. 
 
Dental adverse events 
Dental problems were reported as an AE in 62 patients (1.9%) (CONTROL 27 [1.7%] vs. ZOL 
35 [2.2%]). Jaw pain was reported more frequently in the ZOL arm (CONTROL 7 [0.4%] vs. 
ZOL 29 [1.8%]). One confirmed case of ONJ was reported during adjuvant chemotherapy 
(see below). 
  
Early deaths on treatment 
13 patients died within 6 months of randomisation, (CONTROL 8 [0.5%] vs. ZOL 5 [0.3%]. 
WƌŝŵĂƌǇĐĂƵƐĞƐŽĨĚĞĂƚŚǁŝƚŚŝŶƚŚĞĐŽŶƚƌŽůĂƌŵǁĞƌĞƌĞĐŽƌĚĞĚĂƐ P “ĐŚĞŵŽƚŚĞƌĂƉǇƚŽǆŝĐŝƚǇ ?
(n=4), pneumonia (n=1), septicaemia (n=1), thrombo-embolic disease (n=1) and suicide 
 ?ŶA? ? ) ? WƌŝŵĂƌǇ ĐĂƵƐĞƐ ŽĨ ĚĞĂƚŚ ǁŝƚŚŝŶ ƚŚĞ K> Ăƌŵ ǁĞƌĞ ƌ ĐŽƌĚĞĚ ĂƐ P  “ďƌĞĂƐƚ ĐĂŶĐĞƌ
ƌĞůĂƚĞĚ ?  ?ŶA? ? ) ?  “ĐŚĞŵŽƚŚĞƌĂƉǇ ƚŽǆŝĐŝƚǇ ?  ?ŶA? ? ) ? ƉƵůŵŽŶĂƌǇ ĞŵďŽůƵƐ  ?ŶA? ? ) ? ĐĂƌĚŝĂĐ ĨĂŝůƵƌĞ
(n=1) and unknown (n=1).  
 
Post chemotherapy phase (6 months-3 years) 
During this period ZOL continued to be administered every 3 months from month 9 until 30 
months on study and then every 6 months until 60 months. During this phase no patient 
received chemotherapy. Trastuzumab and/or endocrine therapy were given as per local 
guidelines.  
 
Overall safety profile 
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Overall the administration of ZOL was well-tolerated and without significant additional 
toxicity. SAE were reported in 289 (8.7%) patients (CONTROL 137/1675 [8.2%] vs. ZOL 
152/1665 [9.1%]). 335 SAEs were reported in total (CONTROL 155 vs. ZOL 180). The most 
frequent SAEs occuring in >0.2% of patients are displayed in table 4. No single SAE occurred 
in >1% of patients.  
 
Effects on renal function 
2 cases (<0.1%) of renal failure were described as SAEs, 1 case in each arm. The case of renal 
failure in the patient receiving ZOL occurred in a 44 year old patient following 12 doses of 
ZOL, 1065 days from randomisation. She had acute renal failure and hypercalcaemia, not 
suspected to be related to ZOL.  
 
Other adverse events of interest 
Osteonecrosis of the jaw 
11 patients with confirmed ONJ (0.7%, 95% confidence interval (CI) 0.3% to 1.2%) have been 
reported in the ZOL arm (1 during chemotherapy, 10 in follow-up period) whilst no cases 
have been reported in the control arm (log-rank test = 10.9808, degrees of freedom = 1, p = 
0.0009). Cases were confirmed according to published definitions [8,11]. In 5 patients ONJ 
affected more than one site. All were suspected to be related to treatment with ZOL (Table 
5). An additional four cases in the ZOL arm were reported by the investigator as possible 
ONJ did not meet the diagnostic criteria for a definitive diagnosis.  
 
The case during adjuvant chemotherapy followed a dental abscess requiring extraction after 
the 1
st
 ZOL infusion. Affecting both the mandible and maxilla, the condition was confirmed 
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after the 6
th
 infusion when ZOL was discontinued. Following resolution of ONJ a year later, 
ZOL was reintroduced without any subsequent recurrence  of ONJ.  
 
The median number of ZOL 4mg infusions prior to confirmation of ONJ was 10 (range 6-14). 
The median age of patients at time of confirmation of ONJ was 54 years (range 39-72). 9 
cases underwent a dental extraction prior to the diagnosis of ONJ. The median time from 
randomisation to confirmation of ONJ was 746 days (range 238-1029). Outcomes of cases to 
ĚĂƚĞ ĂƌĞ ĂƐ ĨŽůůŽǁƐ P  “ĐŽŵƉůĞƚĞůǇ ƌĞĐŽǀĞƌĞĚ ? ŶA?4 ?  “ƌĞĐŽǀĞƌĞĚ ǁŝƚŚ ƐĞƋƵĞůĂĞ ? ŶA?2; 
 “ŝŵƉƌŽǀŝŶŐ ?ŶA? ? ? “ĐŽŶĚŝƚŝŽŶƉƌĞƐĞŶƚĂŶĚƵŶĐŚĂŶŐĞĚ ?ŶA?3. 
 
In addition, two patients in the ZOL group developed avascular necrosis (AVN) of the 
femoral head (one bilateral). Both AVN patients had received chemotherapy and 
corticosteroids in the preceding three months. In both cases ZOL was discontinued, 
although a causal association could not be established.  
 
Cardiovascular events 
During chemotherapy, a cardiovascular SAE was reported in 71 (2.2%) patients (CONTROL 
29 [1.8%] vs. ZOL 42 [2.6%]). Between 6 and 36 months, 29 cardiovascular SAE were 
reported (CONTROL 11 [0.7%] vs. ZOL  18 [1.1%]. These events were (CONTROL vs. ZOL 
arm): pulmonary embolus (12 vs. 22); deep vein thrombosis (15 vs. 11); loss of 
consciousness (2 vs. 7); atrial fibrillation/flutter (2 vs. 3); cerebrovascular accident (3 vs. 5); 
transient ischaemic attacks (2 vs. 2); dizziness (1 vs. 2); ventricular tachycardia (1 vs. 0); 
myocardial infarction (1 vs. 3); left ventricular failure (0 vs. 2); palpitations (1 vs. 2); 
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cardiomyopathy (0 vs. 1). None of the events were  suspected to be related to ZOL, and 
differences between groups do not reach statistical significance.  
 
Pregnancies whilst on study 
15 patients from the defined safety population became pregnant (CONTROL 6 vs. ZOL 9). 
Two patients (1 from each arm) became pregnant twice, resulting in a total of 17 
pregnancies. 9 of these pregnancies were aborted (6 planned terminations, 3 spontaneous 
abortions), 7 resulted in live births (CONTROL 3, ZOL 4), while in the remaining case the 
outcome of the pregancy is not known. Of the 4 ZOL treated patients who had a live birth, 
the first had 12 doses and stopped treatment 11 months prior to delivery, the second had 
11 doses, stopping 18 months prior to delivery, the third had 11 doses, stopping 15 months 
prior to delivery, while the fourth received 10 doses but the time between her last 
zoledronic acid treatment cannot be determined.  No overt abnormalities were seen at 
delivery or have been subsequently reported in any of the live births. 
 
New primary cancers 
From randomisation to 3 years follow up, 55 (1.6%) patients have developed a second 
malignancy (CONTROL 30 [1.8%] vs. ZOL 25 [1.5%]). Sites of second cancer were (CONTROL 
vs. ZOL): contralateral breast (8 vs. 10), haematological (3 vs. 3), unknown primary site (6 vs. 
2), skin (2 vs. 3), lung (2 vs. 1), endometrium (0 vs. 3), colon (2 vs. 1), brain (2 vs. 1), bladder 
(2 vs. 0), tongue ( 1 vs. 1), cervix (1 vs. 0) ovary (1 vs. 0).  
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DISCUSSION 
We report the largest safety analysis of zoledronic acid given on an intensive schedule in the 
non-metastatic cancer setting. This extensive body of data from a randomised trial confirms 
that ZOL can be given safely in combination with chemotherapy, without significant impact 
on toxicity of chemotherapy. Although not formally calculated, the similar duration of 
chemotherapy and frequency of dose reductions indicate that ZOL had no clinically relevant 
impact on the dose intensity of chemotherapy.  
 
This is the first study to report on the use of ZOL in the adjuvant setting combined with 
chemotherapy. The ABCSG-12, ZOFAST, Z-FAST, EZO-FAST studies all evaluated ZOL 
alongside hormonal therapy in the adjuvant setting, and with a less intensive 6-monthly 
schedule [5,12,13,14].  As in these trials, with the usual advice given to patients on 
minimising the effects of the acute phase reaction and renal monitoring [15],  the toxicity 
impact of ZOL was minimal with the exception of a low frequency of ONJ. At the time of 
data lock, all patients had completed at least 3 years of treatment and we were in receipt of 
>95% of data related to these treatment. With the possible exception of ONJ, for which 
patients remain at risk throughout years 4 and 5 on treatment (and potentially beyond 
completion of treatment), further additional safety signals of note are unlikely to emerge 
now that treatment administration is on a 6 monthly frequency. However, this will be fully 
evaluated in future reports as the study matures.  
 
The association between bisphosphonate use and ONJ was first described in 2003 [10]. 
Causation has been difficult to prove and the pathogenesis of the condition uncertain and 
probably multifactorial. ONJ is also associated with the use of denosumab [16], suggesting 
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that the suppression of osteoclast numbers and function has a central role in the 
pathophysiology of this condition. However, ONJ has also been reported in association with 
angiogenesis inhibitors such as bevacizumab [17], supporting the notion of mulitple 
aetiological factors. The incidence of ONJ amongst patients receiving oral bisphosphonate 
for osteoporosis is very low (<1 in 10,000), and substantially less than is seen with 
intravenous bisphosphonates for advanced malignancy [11]. In the metastatic setting, it has 
been concluded that dental interventions, disease and treatment related immune 
suppression, duration of exposure and number of bisphosphonate infusions are the most 
significant risk factors for development of the condition [8,11]. The incidence of ONJ in 
metastatic cancer has been estimated at 0.8-12% (2.9-5.3% in breast cancer) [8,11,18,19], 
with an average of approximately 1% per year on treatment [20]. 
 
In AZURE, the low frequency of ONJ (0.7%, 95% CI 0.3% to 1.1%)) is likely to reflect less 
immune suppression than occurs in the metastatic setting, limited exposure to 
chemotherapy, careful monitoring, and conservative dental intervention whenever possible, 
plus the less intensive schedule used once the initial 6 month chemotherapy phase was 
completed. However, the frequency of ONJ appears more than has been reported with 6 
monthly ZOL in the ABCSG-12, ZOFAST, Z-FAST and EZO-FAST studies. Here only two 
possible cases of ONJ have been reported out of >4000 patients [5, 12, 13, 14]. 
 
In advanced cancer, renal effects related to dose, infusion duration and total number of 
infusions of ZOL may be seen [6]. It is likely that in the advanced setting, nephrotoxicity is 
multifactorial, compounded by advancing cancer, co-morbidities and other drugs [21]. 
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However, our results indicate that ZOL given in the adjuvant setting for patients with early 
breast cancer has no significant impact on renal function.  
 
The initial reports of atrial fibrillation (AF) in relation to ZOL use came from outside the 
cancer setting. In the HORIZON study of postmenopausal women with osteoporosis, serious 
AF (new or recurrent) was seen in 1.3% of patients receiving ZOL compared to 0.5% in the 
control arm [22]. No clear association between bisphosphonates and AF could be identified 
in subsequent  safety reviews [23,24]. However, a recent claims based analysis of 6857 
cancer patients aged >65 and receiving bisphosphonates identified an approximate 30% 
increased risk for both AF and supraventricular tachycardias (SVT) when compared with 
matched cancer controls [25]. In our study, it is possible that some non serious episodes of 
AF or other supraventricular tachycardias were not reported as these were not adverse 
events of interest until the initial reports in 2007. However, our findings do  not suggest any 
clinically relevant excess risk for AF with use of zoledronic acid in the adjuvant setting. A 
numerical excess of cardiovascular SAE was reported but there was no significant excess of 
any individual cardiovascular event in the ZOL arm, and very similar numbers of 
arhhythmias. 
 
Bisphosphonates have been shown to cross the placenta in pre-clinical studies, raising 
concern for birth defects [26,27]. The few case reports of bisphosphonate administration 
during pregnancy are, however, reassuring [28,29].  Of the pregnancies which went to term 
in the ZOL arm of AZURE, all were planned and therefore ZOL was stopped before 
conception. Despite this, there remains concern that, due to the long retention time of 
bisphosphonates in bone, foetal exposure may occur even if the drug is stopped long before 
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conception [29]. A recent study of pre-pregnancy or early pregnancy exposure to 
alendronate (n=20) reported no major malformations and 5 spontaneous abortions [30]. In 
another series who received bisphosphonates (not ZOL) within 12 months of conception or 
during the first trimester of pregnancy (n=21), no increased risk of birth defects was seen 
[29]. There were no published reports found of exposure to ZOL and pregnancy outcome, 
but concerns regarding foetal development remain due to the potency and long offset 
duration of ZOL [31].  
 
CONCLUSION 
This safety analysis expands our understanding of the tolerability and risks of ZOL in the 
adjuvant setting and shows that it can be administered safely without compromising 
chemotherapy delivery. A low incidence of ONJ was observed. If the efficacy of adjuvant ZOL 
is confirmed and does become part of standard adjuvant treatment, this report is reassuring 
and predicts for a favourable risk-benefit ratio.  
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Legend to Figures:  
Figure 1:  dƌŝĂůƐĐŚĞŵĂ ? “^ƚĂŶĚĂƌĚƚŚĞƌĂƉǇ ?ƌĞĨĞƌƐƚŽĂŶǇůŽĐĂůůǇĂƉƉƌŽǀĞĚĐǇƚŽƚŽǆŝĐ
chemotherapeutic or endocrine agents 
Figure 2: CONSORT diagram of patient disposition in trial 
 
 
 
 20 
 
Figure 1:  
 
 
                                             
 
 
 
 
 
 
 
 
 
 
 
3360 patients 
Stage II/III 
primary breast 
cancer 
Stratification 
criteria: 
Nodal involvement 
T stage 
ER status 
Systemic therapy 
Statins 
Menopausal status 
Participating centre 
 
R
A
N
D
O
M
I
S
E 
STANDARD THERAPY 
STANDARD THERAPY 
+ 
4mg intravenous zoledronic acid 
 
6 doses               8 doses                             5 doses 
Q3-4 weeks               Q 3 months                                      Q 6 months 
                      6                                          30                                                               60 months 
 21 
Figure 2: 
3360 PATIENTS
CONTROL GROUP
(n= 1680)
ZOLEDRONIC ACID
GROUP ( n=1680 )
CONTROL SAFETY
POPULATION (n=1675) 
ZOLEDRONIC ACID SAFETY
POPULATION (n=1665) 
R
CHEMOTHERAPY 
+/- ENDOCRINE
 (n=1590) 
ENDOCRINE ALONE
 (n=75) 
CHEMOTHERAPY 
+/- ENDOCRINE
 (n=1600) 
ENDOCRINE ALONE
 (n=75) 
Received zoledronic acid in error (n=2)
No data from site (n=3)
Did not start zoledronic acid (n=12)
No data from site (n=3)
 
 
 
Table 1: Table of baseline characteristics and (neo)adjuvant treatments 
 
 CONTROL GROUP ZOL GROUP 
Number Percent Number Percent 
Lymph node involvement 
1 to 3 nodes involved 
A? ?ŶŽĚĞƐŝŶǀŽůǀĞĚ 
Unknown (neoadjuvant) 
Sentinel node +ve - Ax. RT  
 
1007 
565 
100 
3 
 
60.1 
33.7 
6.0 
0.2 
 
1010 
556 
96 
3 
 
60.7 
33.4 
5.8 
0.2 
Tumour stage 
T1 
T2 
T3 
T4 
TX 
 
522 
867 
226 
59 
1 
 
31.2 
51.8 
13.5 
3.5 
0.1 
 
535 
845 
225 
57 
3 
 
32.1 
50.8 
13.5 
3.4 
0.2 
ER status 
ER positive 
ER negative 
ER unknown 
 
1285 
345 
45 
 
76.7 
20.6 
2.7 
 
1281 
345 
39 
 
76.9 
20.7 
2.3 
Neoadjuvant therapy 
Yes 
No 
 
108 
1567 
 
6.4 
93.6 
 
105 
1560 
 
6.3 
93.7 
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Systemic therapy 
Endocrine therapy alone 
Chemotherapy alone 
Endocrine + chemotherapy 
 
75 
360 
1240 
 
4.5 
21.5 
74.0 
 
75 
361 
1229 
 
4.5 
21.7 
73.8 
Anthracyclines 
Yes 
No 
 
1561 
114 
 
93.2 
6.8 
 
1553 
112 
 
93.3 
6.7 
Taxanes 
Yes 
No 
 
383 
1292 
 
22.9 
77.1 
 
385 
1280 
 
23.1 
76.9 
Use of statins 
Yes 
No 
 
100 
1575 
 
6.0 
94.0 
 
94 
1571 
 
5.6 
94.4 
Menopausal status 
Pre-menopausal 
A? ?ǇĞĂƌƐƐŝŶĐĞŵĞŶŽƉĂƵƐĞ 
> 5 years since menopause 
Status unknown 
 
749 
243 
524 
159 
 
44.7 
14.5 
31.3 
9.5 
 
744 
245 
513 
163 
 
44.7 
14.7 
30.8 
9.8 
                                                                                  
 
 Abbreviations: ZOL=zoledronic acid; ER=oestrogen receptor; Ax. RT=axillary radiotherapy 
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                  Control group                      ZOL group 
                     Number (%)                     Number (%) 
Alopecia 1116 (69.8%) 1113 (70.0%) 
Nausea 1034 (64.6%) 1064 (66.9%) 
Fatigue/lethergy 962 (60.1%) 957 (60.2%) 
Constipation 672 (42.0%) 699 (44.0%) 
Vomiting 555 (34.7%) 529 (33.3%) 
Mucositis/stomatitis 525 (32.8%) 514 (32.3%) 
Myalgia/arthralgia* 374 (23.4%) 456 (28.7%) 
Diarrhoea 360 (22.5%) 344 (21.6%) 
Infection 339 (21.2%) 329 (20.7%) 
Stomatitis 275 (17.2%) 283 (17.8%) 
Indigestion 272 (17.0%) 274 (17.2%) 
Skin 286 (17.9%) 254 (16.0%) 
Neutropenia 253 (15.8%) 247 (15.5%) 
Neurosensory 199 (12.4%) 206 (13.0%) 
Hot flushes 172 (10.8%) 173 (10.9%) 
Phlebitis 164 (10.3%) 163 (10.3%) 
Taste disturbance 158 ( 9.9%) 167 (10.5%) 
Headache 154 ( 9.6%) 165 (10.4%) 
 
 
Table 2: Number and percentage of AEs (all grades and occuring in >10% of patients) during adjuvant 
chemotherapy period (randomisation to 6 months).  
 ?
* significant difference noted between treatment groups p = <.05 
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 Control Group ZOL Group 
 Number of 
patients 
Percent Number of 
patients 
Percent 
Neutropenic sepsis 148 9.3 149 9.4 
Neutropenia 46 2.9 38 2.4 
Pyrexia 20 1.3 35 2.2 
Vomiting 21 1.3 33 2.1 
Lower Respiratory Tract 
Infection 
25 1.6 16 1.0 
Central line infection 15 0.9 20 1.3 
Pulmonary Embolus 11 0.7 17 1.1 
                          
 
Table 3: SAEs occurring in >1% patients in either treatment group during the adjuvant chemotherapy period 
(randomisation to 6 months); % represents percentage patients reporting the SAE 
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 Control Group ZOL Group 
 Number Percent Number Percent 
Cellulitis 8 0.5 10 0.6 
Neutropenic sepsis 10 0.6 8 0.5 
New primary breast 
Cancer 
8 0.5 9 0.5 
Chest pain 6 0.4 6 0.4 
Osteonecrosis of Jaw  0 0.0 14* 0.8 
Central line infection 5 0.3 5 0.3 
Wound infection 6 0.4 4 0.2 
Chest infection 5 0.3 4 0.2 
Pyrexia 
Breast infection 
4 
2 
0.2 
0.1 
3 
5 
0.2 
0.3 
 * only 10 confirmed 
 
Table 4: Most frequent SAEs occurring in >0.2% of patients overall from 6 months post-
randomisation to 3 years follow up 
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ONJ 
case 
no. 
Age at  
diagnosis 
of ONJ 
(years) 
No. Doses ZOL 
prior to 
confirmed 
diagnosis of ONJ 
Description of event Outcome of 
event 
1 53 6 Elective admission for tooth extraction 18 days after 
ZOL dose. Tooth extraction site left mandible did not 
heal. Admission for debridement and pain control. 
ONJ confirmed left mandible and right maxilla 
Recovered. 
ZOL restarted 
 without 
sequelae 
2 61 9 Referred to Oral surgery with concerns for ONJ, 
planned debridement and exploration under general 
anaesthetic. ONJ confirmed right and left mandible 
Condition 
present and 
unchanged 
3 67 12 Presented with dental sepsis 6 weeks after 12th 
dose ZOL. Underwent dental clearance revealing pus 
exuding from necrotic maxillary bone. 
Histopathology of bone confirmed necrotic and 
inflammatory change. ONJ confirmed right maxilla 
and mandible 
Recovered 
with  
sequelae 
4 54 10 Presented with possible gum abscess 3 months after 
7
th
 ZOL dose, required tooth extraction and dental 
follow up. ONJ confirmed left maxilla. 
Completely 
recovered 
5 39 9 Patient underwent tooth extraction 3 months after 
8
th
 ZOL dose. Failure to heal and referred to 
maxillofacial surgery. ONJ right mandible 
Condition 
present and 
unchanged 
6 72 12 Simple tooth extraction, unconfirmed timing relating 
to ZOL dose. Ongoing problems with swelling around 
site of extraction. Several courses of antibiotics but 
exposed bone remains in upper mandible. ONJ 
confirmed mandible. Ongoing assessment by 
maxillofacial surgeons.. 
Condition 
present and 
unchanged 
7 63 13 Simple tooth extraction while on treatment. 2 
months after 13 dose ZOL. Patient presented with 
painful jaw and possible infection. Underwent 
debridement revealing a piece of bone, continues on 
antibiotics. ONJ confirmed left maxilla 
Completely 
healed 
8 54 8 Jaw pain since simple dental extraction 5 months 
after 8
th
 dose ZOL. 9
th
 dose omitted. At next follow 
up exposed bone of lower mandible. Confirmed ONJ 
left mandible 
Recovered 
with  
sequelae 
9 43 14 Tooth extraction whilst on treatment with delayed 
healing of extraction site. Exposed bone confirmed 
in clinic. Treated with antibiotics and mouthwashes.  
Condition 
improving 
10 53 8 Presented with purulent discharge left canine tooth. 
Referred to maxillofacial surgeons. Granulation 
tissue and infection within defect around previously 
extracted tooth with radiographic changes. 
Confirmed ONJ left mandible and maxilla 
Completely 
recovered 
11 67 14 Underwent 3 dental extractions 3 months after 14
th
 
ZOL dose. Persistent soreness of mouth. Exposed 
bone confirmed by dental hospital. Confirmed ONJ 
left mandible and right maxilla. 
Condition 
improving 
 
 
Table 5: Details of the 11 confirmed ONJ cases. 
